Latest Articles

Publication Date
“We must reject the normalization of female pain”: Lupita Nyong’o teams up with lawmakers after sharing her fibroids journey on social media - The Daily Dot

“We must reject the normalization of female pain”: Lupita Nyong’o teams up with lawmakers after sharing her fibroids journey on social media The Daily Dot

Published: July 21, 2025, 6 p.m.
Clinical challenge of benign metastasizing leiomyoma with cardiac and hepatic involvement: A case report.

Benign metastasizing leiomyoma (BML) is a rare disorder occurring in women with a history of uterine leiomyomas and having detection of leiomyomas in extrauterine locations. This case report describes a …

Published: July 7, 2025, midnight
UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told - The Malaysian Reserve

UFE Doesn’t Remove Fibroids–Here’s What Women Aren’t Being Told The Malaysian Reserve

Published: June 26, 2025, 10:51 a.m.
UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told - StreetInsider

UFE Doesn't Remove Fibroids--Here's What Women Aren't Being Told StreetInsider

Published: June 25, 2025, 10:14 a.m.
UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told - Morningstar

UFE Doesn't Remove Fibroids—Here's What Women Aren't Being Told Morningstar

Published: June 25, 2025, 10 a.m.
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health

The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health

Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace

Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times

Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire

Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스

TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스

Published: May 7, 2025, noon
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!